How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,595 results for

Intrauterine Device

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Comment on 'Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial'. (PubMed)

Comment on 'Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial'. 28756404 2018 07 05 2045-2098 43 4 2017 Oct The journal of family planning and reproductive health care J Fam Plann Reprod Health Care Comment on 'Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial'. 342 10.1136/jfprhc (...) @stanford.edu. eng Letter 2017 07 29 England J Fam Plann Reprod Health Care 101087687 1471-1893 hormonal contraception human immunodeficiency virus intrauterine systems long-acting progestogens long-acting reversible contraception Competing interests: None declared. 2017 8 2 6 0 2017 8 2 6 1 2017 7 31 6 0 ppublish 28756404 jfprhc-2017-101827 10.1136/jfprhc-2017-101827

2017 The Journal of Family Planning and Reproductive Health Care

102. Comments on manuscript: vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective cesarean section: a randomized double-blind clinical trial. (PubMed)

Comments on manuscript: vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective cesarean section: a randomized double-blind clinical trial. 28189667 2017 10 19 2018 12 02 1879-0518 95 4 2017 04 Contraception Contraception Comments on manuscript: vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective cesarean section: a randomized double-blind clinical trial. 434-435 S0010-7824(17)30038-0 10.1016/j.contraception (...) . 2017 Apr;95(4):435 28188744 Administration, Intravaginal Cesarean Section Double-Blind Method Female Humans Intrauterine Devices Misoprostol Pregnancy 2017 01 20 2017 01 21 2017 2 13 6 0 2017 10 20 6 0 2017 2 13 6 0 ppublish 28189667 S0010-7824(17)30038-0 10.1016/j.contraception.2017.01.012

2017 Contraception

103. Lidocaine for Pain Control During Intrauterine Device Insertion

Lidocaine for Pain Control During Intrauterine Device Insertion Lidocaine for Pain Control During Intrauterine Device Insertion - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lidocaine for Pain Control (...) During Intrauterine Device Insertion The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03362905 Recruitment Status : Not yet recruiting First Posted : December 5, 2017 Last Update Posted : December 5, 2017 See Sponsor: Ain

2017 Clinical Trials

104. Vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective Cesarean section: a randomized double-blind clinical trial. (PubMed)

Vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective Cesarean section: a randomized double-blind clinical trial. The current study aims to evaluate if vaginal misoprostol (400 mcg) administered prior to intrauterine device (IUD) insertion increases the ease and success of insertion among women who had delivered only by elective cesarean delivery (CD).The current study was a randomized, double-blind, placebo-controlled trial conducted in Assiut Women's

2017 Contraception

105. Vesical transmigration of an intrauterine contraceptive device: A rare case report and literature review. (PubMed)

Vesical transmigration of an intrauterine contraceptive device: A rare case report and literature review. Displacement of an intrauterine contraceptive device (IUD) is a rare and serious complication of IUD insertion. Theoretically, it can migrate to anywhere in the pelvic and abdominal cavity. However, it is not usual for an IUD to migrate to the bladder.In this case report, we reported a patient with chronic urinary symptoms caused by the migration of an IUD into the bladder. The displacement

Full Text available with Trip Pro

2017 Medicine

106. Society of Family Planning Guidelines: Postplacental insertion of intrauterine devices. (PubMed)

Society of Family Planning Guidelines: Postplacental insertion of intrauterine devices. Postplacental intrauterine device (IUD) placement, defined as IUD placement within 10 min after delivery of the placenta, is an appealing strategy for increasing access to postpartum IUDs because it does not require a separate postpartum visit. These guidelines present an evidence-based assessment of postplacental IUD placement after vaginal and cesarean delivery. Postplacental IUD insertion is safe and does

2017 Contraception

107. Frequency of 6-week follow-up appointment scheduling after intrauterine device insertion. (PubMed)

Frequency of 6-week follow-up appointment scheduling after intrauterine device insertion. Long-acting reversible contraception (LARC) is widely recommended to reduce unintended pregnancy in the USA. As intrauterine device (IUD) use increases, evaluating the role of post-insertion follow-up is important.A retrospective patient record review was conducted to assess the follow-up experience of women who had an IUD placed at the University of Kansas Medical Center from 1 January to 30 June 2015

2017 Journal of Family Planning and Reproductive Health Care

108. Six-week retention after post-placental copper intrauterine device placement. (PubMed)

Six-week retention after post-placental copper intrauterine device placement. We sought to evaluate the 6-week clinical outcomes (intrauterine device [IUD] retention, recognized expulsions, ability to visualize or palpate strings, and need for ultrasound evaluation) in women who received a TCu380A postplacental IUD (PPIUD) after vaginal (VD) or cesarean delivery (CD).We conducted a retrospective cohort study to examine the 6-week retention of TCu380A IUDs placed within 10 min of placental

2017 Contraception

109. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. (PubMed)

Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. To assess efficacy of the levonorgestrel-releasing intrauterine device (LNG-IUD) for treatment of complex atypical hyperplasia or low-grade endometrial cancer.This retrospective case series included all patients treated with the LNG-IUD for complex atypical hyperplasia or early-grade endometrial cancer from January 2003 to June 2013. Response rates were calculated

2017 Obstetrics and Gynecology

110. Social media and the intrauterine device: a YouTube content analysis. (PubMed)

Social media and the intrauterine device: a YouTube content analysis. YouTube's online archive of video testimonials related to health information are more commonly viewed than those developed by clinicians and professional groups, suggesting the importance of the patient experience to viewers. We specifically sought to examine the accuracy of information on, and projected acceptability of, the intrauterine device (IUD) from these YouTube testimonials.We searched YouTube for videos about (...) individual uploaders' IUD experiences, using the search terms 'intrauterine device', 'IUD', 'Mirena' and 'Paragard'. Given interest in user testimonials, we excluded professional and instructional videos belonging to commercial or non-profit entities. Two reviewers independently analysed the videos using a structured guide, with attention to inaccurate information.Of 86 identified videos, four videos featured clinicians and were excluded; 62 met inclusion criteria. Interrater agreement on IUD portrayal

2017 Journal of Family Planning and Reproductive Health Care

111. Anticipated Pain as a Predictor of Discomfort with Intrauterine Device Placement. (PubMed)

Anticipated Pain as a Predictor of Discomfort with Intrauterine Device Placement. Intrauterine devices have been gaining popularity for the past 2 decades. Current data report that >10% of women who use contraception are using an intrauterine device. With <1% failure rates, the intrauterine device is one of the most effective forms of long-acting reversible contraception, yet evidence shows that fear of pain during intrauterine device placement deters women from choosing an intrauterine device (...) as their contraceptive method.The objective of this analysis was to estimate the association between anticipated pain with intrauterine device placement and experienced pain. We also assessed other factors associated with increased discomfort during intrauterine device placement. We hypothesized that patients with higher levels of anticipated pain would report a higher level of discomfort during placement.We performed a secondary analysis of the Contraceptive CHOICE Project. There were 9256 patients enrolled

Full Text available with Trip Pro

2017 American Journal of Obstetrics and Gynecology

112. Intrauterine Device Use and Cervical Cancer Risk: A Systematic Review and Meta-analysis. (PubMed)

Intrauterine Device Use and Cervical Cancer Risk: A Systematic Review and Meta-analysis. To estimate the association between use of an intrauterine device (IUD) and risk of cervical cancer by subjecting existing data to critical review, quantitative synthesis, and interpretation.We searched PubMed, Web of Science, ClinicalTrials.gov, and catalogs of scientific meetings and abstracts, theses, and dissertations queried from inception through July 2016.Examination of abstracts from 225 reports

2017 Obstetrics and Gynecology

113. Women's experiences with immediate postpartum intrauterine device insertion: A mixed methods study. (PubMed)

Women's experiences with immediate postpartum intrauterine device insertion: A mixed methods study. To describe women's pain and experiences with immediate postpartum intrauterine device (IUD) insertion (IPPI) following vaginal delivery using a ring forceps insertion technique.This observational mixed-methods study included women who underwent successful IPPI using ring forceps, with and without epidural analgesia. To describe women's pain during the procedure, we recruited women during

2017 Contraception

114. Practice Bulletin No. 186 Summary: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. (PubMed)

Practice Bulletin No. 186 Summary: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Intrauterine devices and contraceptive implants, also called long-acting reversible contraceptives (LARC), are the most effective reversible contraceptive methods. The major advantage of LARC compared with other reversible contraceptive methods is that they do not require ongoing effort on the part of the patient for long-term and effective use. In addition, after the device is removed

2017 Obstetrics and Gynecology

115. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. (PubMed)

Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Intrauterine devices and contraceptive implants, also called long-acting reversible contraceptives (LARC), are the most effective reversible contraceptive methods. The major advantage of LARC compared with other reversible contraceptive methods is that they do not require ongoing effort on the part of the patient for long-term and effective use. In addition, after the device is removed

2017 Obstetrics and Gynecology

116. Postplacental intrauterine device expulsion by 12 weeks: A prospective cohort study. (PubMed)

Postplacental intrauterine device expulsion by 12 weeks: A prospective cohort study. An intrauterine device placed immediately following a delivery can serve as an effective and safe contraceptive strategy in the postpartum period. There is limited evidence that the levonorgestrel intrauterine system may have a higher rate of expulsion compared to the copper intrauterine device; however, rates of expulsion for these 2 intrauterine device types have not been compared directly.We sought (...) to compare expulsion rates by 12 weeks' postpartum for the levonorgestrel intrauterine system and copper intrauterine device.We enrolled women who received postplacental intrauterine devices at 2 urban hospitals. Eligible women were ≥18 years old, English- or Spanish-speaking, with singleton vaginal delivery at ≥35 weeks' gestation. Intrauterine devices were inserted within 10 minutes of placental delivery by trained providers using ring forceps or the operator's hand. Intrauterine device location

2017 American Journal of Obstetrics and Gynecology

117. One-year continuation of copper or levonorgestrel intrauterine devices initiated at the time of emergency contraception. (PubMed)

One-year continuation of copper or levonorgestrel intrauterine devices initiated at the time of emergency contraception. This study compares 1-year intrauterine device (IUD) continuation among women presenting for emergency contraception (EC) and initiating the copper (Cu T380A) IUD or the levonorgestrel (LNG) 52 mg IUD plus 1.5 mg oral LNG.This cohort study enrolled 188 women who presented at a single family planning clinic in Utah between June 2013 and September 2014 and selected either (...) for 147 (84%) participants, 33 (22%) had requested removals, 13 (9%) had an expulsion and declined reinsertion, 3 (2%) had a pregnancy with their IUD in place and 98 (67%) were still using their device. Continuation rates did not differ by IUD type; 60% of Cu T380A IUD users and 70% of LNG 52 mg IUD plus oral LNG users were still using their device at 12 months (adjusted hazard ratio 0.72, 95% confidence interval 0.40-1.3).Two-thirds of women who chose IUD placement at the EC clinical encounter

Full Text available with Trip Pro

2017 Contraception

118. Short-term copper intrauterine device placement improves the implantation and pregnancy rates in women with repeated implantation failure. (PubMed)

Short-term copper intrauterine device placement improves the implantation and pregnancy rates in women with repeated implantation failure. To study if hysteroscopy and short-term copper intrauterine device placement (Cu-IUD) improves the pregnancy rates of women with repeated implantation failure (RIF) undergoing frozen-thawed embryo transfer (FET).Retrospective study.Medical university hospital.Infertile women with at least two implantation failures with the use of at least one good-quality (...) embryo.All patients received operative hysteroscopy in the follicular cycle, and if endometrial polyps, polypoid endometrium, or intrauterine adhesions were found they were removed. In some patients, a Cu-IUD was inserted immediately after hysteroscopy and removed after two menstrual periods before embryo implantation. All patients underwent in vitro fertilization or intracytoplasmic sperm injection and FET.Clinical pregnancy and implantation rates.A total of 440 women with a mean age of 33.42 ± 4.45

2017 Fertility and Sterility

119. Uterine perforation by intrauterine devices: a 16-year review. (PubMed)

Uterine perforation by intrauterine devices: a 16-year review. One of the major concerns with the insertion of intrauterine devices is uterine perforation. Though uncommon, it can be debilitating and result in failure of the device. In this article we review uterine perforation with intrauterine contraception (IUC) in a community clinic in the UK over a 16-year period.We prospectively collected data on uterine perforations for the years 2000-2015, reviewed associated factors and calculated (...) limits. Twenty-eight of the perforations were in parous women, 87% of whom were within 18 weeks of delivery, peaking at 13 weeks postpartum. Twenty of these were in breastfeeding women. In 3/28 cases for which we have outcome data the device was adherent to or had perforated either the bladder or bowel.Our perforation rate is consistent with other studies. Most of our perforations were within 18 weeks of childbirth, earlier than in a recent major study. We cannot tell from our data if there is a true

2017 Journal of Family Planning and Reproductive Health Care

120. Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. (PubMed)

Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. To assess the endometrial response rates to treatment with the levonorgestrel intrauterine device in post-menopausal women with atypical hyperplasia/endometrial intraepithelial neoplasia and grade 1 endometrioid (AH/EC) endometrial carcinoma who are not surgical candidates.Chart review was undertaken of patients with AH/EC (...) who underwent levonorgestrel intrauterine device insertion by a gynecologic oncologist within two academic health systems between 2002 and 2013. When available, tissue blocks were evaluated with immunohistochemical staining for progesterone receptor expression.A total of 41 patients received treatment for AH/EC with the levonorgestrel intrauterine device. Follow up sufficient to assess response occurred in 36 women (88%). Complete response was documented in 18 of 36 women (50%), no response in 8

2017 Gynecologic Oncology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>